ramosetron has been researched along with fluorouracil in 5 studies
| Studies (ramosetron) | Trials (ramosetron) | Recent Studies (post-2010) (ramosetron) | Studies (fluorouracil) | Trials (fluorouracil) | Recent Studies (post-2010) (fluorouracil) |
|---|---|---|---|---|---|
| 194 | 94 | 83 | 45,562 | 9,307 | 14,663 |
| Protein | Taxonomy | ramosetron (IC50) | fluorouracil (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.32 | |
| Thymidylate synthase | Mus musculus (house mouse) | 1.58 | |
| Aromatase | Homo sapiens (human) | 0.63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K | 1 |
| Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T | 1 |
| Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY | 1 |
| Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M | 1 |
2 trial(s) available for ramosetron and fluorouracil
| Article | Year |
|---|---|
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Appetite; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Nausea; Safety; Serotonin Antagonists; Treatment Outcome; Vomiting | 1999 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Squamous Cell; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Nausea; Vomiting, Anticipatory | 2005 |
3 other study(ies) available for ramosetron and fluorouracil
| Article | Year |
|---|---|
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Esophageal Neoplasms; Fluorouracil; Humans; Male; Metoclopramide; Middle Aged; Nausea; Organoplatinum Compounds; Serotonin Antagonists; Stomach Neoplasms; Vomiting, Anticipatory | 2005 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; Metoclopramide; Middle Aged; Nausea; Ondansetron; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Vomiting | 2009 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; Colonic Neoplasms; Cytokines; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Fluorouracil; Gastrointestinal Agents; Gene Expression Regulation; Immunosuppressive Agents; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mucositis; Ondansetron; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists | 2013 |